Rezera (RZRA) IPO deck
Rezera is a clinical-stage biotechnology company developing proprietary oral NLRP3 inhibitors to target sterile inflammation in cardiovascular and neuroinflammatory diseases.
Rezera is a clinical-stage biotechnology company developing proprietary oral NLRP3 inhibitors to target sterile inflammation in cardiovascular and neuroinflammatory diseases.
%20IPO%20deck){kind=link}